New asthma drug passes first safety hurdle in small trial
NCT ID NCT05366764
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested the safety and tolerability of a new drug called SAR443765 in 36 people, including healthy volunteers and those with mild-to-moderate asthma. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moved through the body. The goal was to see if the drug is safe enough for further testing, not to measure its effectiveness against asthma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR443765 (an injectable drug)
What this could lead to
If successful, this could point toward a new treatment option for asthma that helps control symptoms.
What could go wrong
This is a very early Phase 1 trial with only 36 participants, focused on safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 2760001
Berlin, Germany
-
Investigational Site Number : 8260001
Belfast, BT9 6AD, United Kingdom